Misc - HINOTSU Shiro

有効性・安全性 ロサルタンJ-PEMの中間報告

三溝 和男, 樋之津 史郎, 河邊 絵里, 横塚 美規, 溝越 惠美子, 森田 康子, 佐藤 嗣道, 久保田 潔

薬剤疫学 ( (一社)日本薬剤疫学会 )  5 ( Suppl. ) S58 - S59  2000.10

日本版処方-イベントモニタリング(J-PEM)で報告されたイベントの医師-薬剤師間の一致性とそのシグナル生成における重要性

佐藤 嗣道, 樋之津 史郎, 河邊 絵里, 森田 康子, 横塚 美規, 青山 美砂子, 三溝 和男, 久保田 潔

薬剤疫学 ( (一社)日本薬剤疫学会 )  5 ( Suppl. ) S50 - S51  2000.10

分子標的治療薬(Molecular Targeted Therapeutics)の臨床開発における日本と世界の比較

赤座 英之, 相羽 恵介, 礒西 成治, 小川 修, 渋谷 昌彦, 曽根 三郎, 鶴尾 隆, 野口 眞三郎, 樋之津 史郎, 古野 純典, 三上 修, Blackledge George, Vose Brent, Stribling Don

癌と化学療法 ( (株)癌と化学療法社 )  27 ( 11 ) 1681 - 1693  2000.10

【小児がんのグループスタディをめぐって】 日本におけるウィルムス腫瘍のグループスタディとそのねらい

岩川 眞由美, 大川 治夫, 大橋 鎮雄, 金子 安比古, 土田 嘉昭, 恒松 由記子, 秦 順一, 樋之津 史郎, 山田 正夫, 横森 欣司, 日本ウィルムス腫瘍グループ

小児外科 ( (株)東京医学社 )  32 ( 8 ) 792 - 797  2000.08

小児悪性腫瘍の診断と治療戦略 日本Wilms腫瘍study groupの治療・研究戦略

岩川 眞由美, 大川 治夫, 大橋 鎮雄, 金子 安比古, 土田 嘉昭, 恒松 由記子, 秦 順一, 樋之津 史郎, 山田 正夫, 横森 欣司

日本外科系連合学会誌 ( 日本外科系連合学会 )  25 ( 3 ) 556 - 556  2000.06

日本版処方-イベントモニタリング(J-PEM)で保険薬局の薬剤師からの情報を病院薬局の薬剤師からの情報で補う必要性について J-PEMパイロットスタディにおける検討

三溝 和男, 樋之津 史郎, 青山 美砂子, 横塚 美規, 森田 康子, 河邊 絵里, 佐藤 嗣道, 浜田 知久馬, 久保田 潔

薬剤疫学 ( (一社)日本薬剤疫学会 )  5 ( 1 ) 11 - 24  2000.06

　View Summary

保険薬局と仲介院内薬剤部からの質問票の回答を比較して,今後の「我が国における英国PEM(Prescription-Event Monitoring)類似のイベントモニタリングを実施する為の条件に関する研究」において,保険薬局が登録した患者に関して保険薬局から得られた情報を仲介院内薬剤部から得られた情報で補う必要があるかを検討した.その結果,仲介院内薬剤部の薬剤師からも情報を得る必要性は大きくないと判断された

DOI

Re: Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor - Reply

M Tomobe, T Shimazui, K Uchida, S Hinotsu, H Akaza

JOURNAL OF UROLOGY ( LIPPINCOTT WILLIAMS & WILKINS )  163 ( 5 ) 1525 - 1525  2000.05

Rapid communication, short report, research note, etc. (scientific journal)  

表在性膀胱腫瘍に対する塩酸エピルビシン・膀胱内注入療法の腫瘍再発予防効果 尿路癌ADM/FARM研究会・第六次研究の結果

黒田 昌男, 新島 端夫, 古武 敏彦, 赤座 英之, 樋之津 史郎, 大橋 靖雄, 松村 陽右, 小磯 謙吉, 岡島 英五郎, 井坂 茂夫

日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  91 ( 3 ) 175 - 175  2000.03

DOI CiNii

表在性膀胱癌経尿道的腫瘍切除後の早期再発に対する抗癌剤膀胱内注入療法の再発予防効果 ハザードのスムージングを用いた複数臨床研究の併合解析

樋之津 史郎, 赤座 英之, 大橋 靖雄, 古武 敏彦

日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  91 ( 3 ) 175 - 175  2000.03

DOI CiNii

Status of kidney transplantation in Japan.(共著)

Clinal Transplantation 2000     374 - 375  2000

Status of kidney transplantation in Japan.(共著)

Clinal Transplantation 2000     374 - 375  2000

Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection - A combined analysis of trials by the Japanese urological cancer research croon using smoothed hazard function

S Hinotsu, H Akaza, Y Ohashi, T Kotake

CANCER ( WILEY-LISS )  86 ( 9 ) 1818 - 1826  1999.11

　View Summary

BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as "primary and solitary," "primary and multiple," "recurrent and solitary," or "recurrent and multiple." RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase. (C) 1999 American Cancer Society.

DOI PubMed CiNii

Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection - A combined analysis of trials by the Japanese urological cancer research croon using smoothed hazard function

S Hinotsu, H Akaza, Y Ohashi, T Kotake

CANCER ( WILEY-LISS )  86 ( 9 ) 1818 - 1826  1999.11

　View Summary

BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as "primary and solitary," "primary and multiple," "recurrent and solitary," or "recurrent and multiple." RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase. (C) 1999 American Cancer Society.

DOI PubMed CiNii

情報ネットワークを用いた日本ウィルムス腫瘍グループスタディー

恒松 由記子, 岩川 真由美, 大川 治夫, 大橋 靖雄, 金子 安比古, 土田 嘉昭, 秦 順一, 樋之津 史郎, 美杉 和章, 山田 正夫

小児がん ( (NPO)日本小児がん学会 )  36 ( 3 ) 412 - 412  1999.11

日本版処方-イベントモニタリング(J-PEM)のパイロットスタディーにおける院外保険薬局と院内薬剤部への質問票に対する回答の比較

三溝 和男, 樋之津 史郎, 横塚 美規, 青山 美砂子, 森田 康子, 浜田 知久馬, 久保田 潔

薬剤疫学 ( (一社)日本薬剤疫学会 )  4 ( Suppl. ) S32 - S33  1999.10

【Wilms腫瘍の診断と最近の治療】 情報ネットワークを用いた日本ウィルムス腫瘍グループスタディ

岩川 眞由美, 土田 嘉昭, 秦 順一, 山田 正夫, 恒松 由記子, 金子 安比古, 大橋 靖雄, 樋之津 史郎, 横森 欣司

日本癌治療学会誌 ( (一社)日本癌治療学会 )  34 ( 2 ) 90 - 90  1999.10

小児がんの治療・基礎と臨床の接点 わが国のWilms腫瘍とWT1遺伝子異常の特徴 日本ウイルムス腫瘍スタディーグループの活動を中心に

秦 順一, 岩川 真由美, 大川 治夫, 大橋 靖雄, 金子 安比古, 土田 嘉昭, 恒松 由記子, 樋之津 史郎, 三杉 和章, 山田 正夫

日本小児外科学会雑誌 ( (NPO)日本小児外科学会 )  35 ( 3 ) 395 - 395  1999.05

Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy

K Uchida, H Akaza, K Hattori, R Noguchi, F Kondo, S Ishikawa, M Ohtani, S Hinotsu, K Koiso

JAPANESE JOURNAL OF CLINICAL ONCOLOGY ( OXFORD UNIV PRESS )  29 ( 2 ) 87 - 91  1999.02

　View Summary

Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m(2) and methotrexate 30 mg/m(2) were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 mu g/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase tan evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P< 0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P< 0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.

DOI PubMed CiNii

Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy

K Uchida, H Akaza, K Hattori, R Noguchi, F Kondo, S Ishikawa, M Ohtani, S Hinotsu, K Koiso

JAPANESE JOURNAL OF CLINICAL ONCOLOGY ( OXFORD UNIV PRESS )  29 ( 2 ) 87 - 91  1999.02

　View Summary

Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m(2) and methotrexate 30 mg/m(2) were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 mu g/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase tan evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P< 0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P< 0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.

DOI PubMed CiNii

情報ネットワークを用いた日本ウィルムス腫瘍グループスタディ

岩川 真由美, 大川 治夫, 大橋 靖雄, 金子 安比古, 土田 嘉昭, 恒松 由記子, 秦 順一, 樋之津 史郎, 三杉 和章, 山田 正夫

日本外科学会雑誌 ( (一社)日本外科学会 )  100 ( 臨増 ) 77 - 77  1999.02

CiNii